U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07783659) titled 'Zotatifin And EIF4A Platinum Helix Inhibition In Resistant AdvancedTNBC' on Aug. 21.
Brief Summary: To find the optimal (best) recommended dose of zotatifin and carboplatin to treat patients with metastatic or recurrent TNBC.
Study Start Date: Feb. 12, 2027
Study Type: INTERVENTIONAL
Condition:
Phase IB
Zotatifin
EIF4A
Advanced TNBC
Platinum Helix Inhibition
Intervention:
DRUG: Zotatifin
Given by IV
DRUG: carboplatin
Given by IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Disclaimer: Curated by HT Syndication....